Organon & Co. (NYSE:OGN) SVP Buys $353,080.80 in Stock

Organon & Co. (NYSE:OGN) SVP Lynette Holzbaur acquired 26,448 shares of the stock in a transaction dated Wednesday, May 6th. The stock was acquired at an average cost of $13.35 per share, with a total value of $353,080.80. Following the transaction, the senior vice president directly owned 52,851 shares in the company, valued at approximately $705,560.85. This represents a 100.17% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Organon & Co. Trading Up 0.2%

Shares of NYSE:OGN opened at $13.35 on Friday. The business’s 50-day moving average is $8.00 and its 200 day moving average is $7.82. The company has a debt-to-equity ratio of 9.47, a current ratio of 1.97 and a quick ratio of 1.23. Organon & Co. has a 1 year low of $5.69 and a 1 year high of $13.44. The firm has a market capitalization of $3.50 billion, a P/E ratio of 14.35, a P/E/G ratio of 1.24 and a beta of 1.57.

Organon & Co. (NYSE:OGN) last issued its quarterly earnings results on Thursday, April 30th. The company reported $0.71 earnings per share for the quarter, missing analysts’ consensus estimates of $0.83 by ($0.12). Organon & Co. had a return on equity of 99.95% and a net margin of 3.99%.The business had revenue of $1.46 billion for the quarter, compared to analysts’ expectations of $1.49 billion. During the same quarter in the previous year, the firm posted $1.02 EPS. Organon & Co.’s revenue was down 3.5% on a year-over-year basis. On average, research analysts predict that Organon & Co. will post 3.23 earnings per share for the current fiscal year.

Organon & Co. Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 11th. Shareholders of record on Monday, May 11th will be given a dividend of $0.02 per share. This represents a $0.08 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Monday, May 11th. Organon & Co.’s payout ratio is currently 8.60%.

Analyst Ratings Changes

A number of research firms have issued reports on OGN. Piper Sandler raised shares of Organon & Co. from an “underweight” rating to a “neutral” rating and raised their price target for the stock from $5.00 to $14.00 in a report on Tuesday, April 28th. Wall Street Zen downgraded Organon & Co. from a “buy” rating to a “hold” rating in a research report on Saturday, January 31st. BNP Paribas Exane restated a “neutral” rating and issued a $14.00 target price (up from $12.00) on shares of Organon & Co. in a research note on Wednesday, April 29th. Barclays lifted their price target on Organon & Co. from $7.50 to $8.00 and gave the stock an “underweight” rating in a research report on Tuesday, February 24th. Finally, Zacks Research upgraded Organon & Co. from a “strong sell” rating to a “hold” rating in a research note on Tuesday, April 14th. Four equities research analysts have rated the stock with a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Reduce” and a consensus price target of $11.40.

Institutional Investors Weigh In On Organon & Co.

Hedge funds have recently modified their holdings of the company. AQR Capital Management LLC increased its position in shares of Organon & Co. by 105.2% in the fourth quarter. AQR Capital Management LLC now owns 8,570,958 shares of the company’s stock valued at $61,282,000 after buying an additional 4,394,814 shares in the last quarter. Vanguard Group Inc. grew its stake in Organon & Co. by 11.3% in the 3rd quarter. Vanguard Group Inc. now owns 35,928,403 shares of the company’s stock valued at $383,715,000 after acquiring an additional 3,650,860 shares during the period. UBS Group AG grew its stake in Organon & Co. by 55.2% in the 4th quarter. UBS Group AG now owns 4,295,002 shares of the company’s stock valued at $30,795,000 after acquiring an additional 1,527,492 shares during the period. Private Management Group Inc. increased its holdings in Organon & Co. by 38.3% in the 4th quarter. Private Management Group Inc. now owns 4,347,073 shares of the company’s stock worth $31,169,000 after acquiring an additional 1,204,979 shares in the last quarter. Finally, Balyasny Asset Management L.P. increased its holdings in Organon & Co. by 102.1% in the 3rd quarter. Balyasny Asset Management L.P. now owns 2,240,149 shares of the company’s stock worth $23,925,000 after acquiring an additional 1,131,941 shares in the last quarter. 77.43% of the stock is owned by hedge funds and other institutional investors.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.